Can we control tuberculosis in high HIV prevalence settings? Godfrey-Faussett P, Ayles H. Elsevier, Tuberculosis (2003) 83, 68-76.

The Growing Burden of Tuberculosis; Global Trends and Interactions with the HIV Epidemic. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. Arch Intern Med 2003;163:1009-1021.

ProTEST Lessons Learned Workshop. Durban, South Africa 3-6 February 2003. World Health Organization. View "Background" at: http://www.who.int/gtb/TBHIV/Durban_feb03/index.htm

Stable Incidence Rates of Tuberculosis (TB) among Human Immunodeficiency Virus (HIV)-Negative South African Gold Miners during a Decade of Epidemic HIV-Associated TB. Corbett E, Charalambous S, Fielding K, Clayton T, Hayes R, De Cock K, Churchyard G. JID 2003:188:1156-63.

Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? Churchyard GJ, Fielding K, Charalambous S, Day JH, Corbett EL, Hayes RJ, Chaisson RE, DeCock KM, Samb B, Grant AD. AIDS 2003, 17:2063-2070.

What is the limit to case detection under the DOTS strategy for tuberculosis control? Dye C, Watt CJ, Bleed DM, Williams BG. Elsevier, Tuberculosis (2003) 83, 35-43.

The politics of 'branding' in policy transfer: the case of DOTS for tuberculosis control. Ogden J, Walt G, Lush L. Elsevier, Social Science & Medicine: 57 (2003) 179-188.

HIV Disease Progression and Effects of Tuberculosis Prevention Therapy in HIV-Infected Adults. Yun HJ,
Whalen CC, Okwera A, Mugerwa RD, Ellner JJ.